Welcome to our dedicated page for Roivant Sciences news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences (ROIV) is a commercial-stage biopharmaceutical company pioneering accelerated drug development through its innovative 'vant' subsidiary model. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical milestones, regulatory developments, and strategic partnerships.
Our curated collection of ROIV press releases and verified news articles serves as a comprehensive resource for tracking the company's progress in immunology, dermatology, and autoimmune therapeutics. Users will find updates spanning clinical trial results, FDA communications, licensing agreements, and operational developments across Roivant's network of specialized subsidiaries.
The page features essential updates including new drug applications, partnership announcements with academic institutions, and pipeline expansion into novel therapeutic areas. All content is organized chronologically to help users monitor the company's execution of its unique drug development strategy.
Bookmark this page for direct access to primary source materials from Roivant Sciences, including SEC filings and peer-reviewed research collaborations. Check regularly for updates on how the company's agile approach continues to reshape biopharmaceutical innovation.
Roivant (Nasdaq: ROIV) reported its Q4 and FY2024 results, highlighting strong performance in clinical trials and significant debt reductions.
Key points include:
- Brepocitinib showed the best treatment failure rates in non-infectious uveitis (NIU), supporting a pivotal program initiation in H2 2024.
- VTAMA net product revenue reached $75.1M, with over 385,000 prescriptions since launch.
- Roivant renegotiated Dermavant’s debt, reducing potential cash payments by over $300M, with $225M savings expected over the next three fiscal years.
- The company has $6.6B in cash, supporting a runway into profitability.
- A $1.5B share repurchase program was approved, reducing outstanding shares by 9%.
- Net loss for Q4 was $108M, while annual R&D expenses decreased by $23.5M.
Roivant (Nasdaq: ROIV) announced a live conference call and webcast scheduled for 8:00 a.m. ET on May 30, 2024, to discuss its fourth-quarter and fiscal year results ending March 31, 2024. The company will also provide a business update during this session. Investors can register online for the conference call. The presentation will be available under the 'Events & Presentations' section of Roivant’s website, where the archived webcast will also be accessible post-call.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
